Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

These two companies are leaders in their respective industries with a long history of success. Both have a habit of delivering solid financial results and increasing their dividend payouts.

Want Passive Income Forever? Buy These 2 Magnificent Stocks Now

Amgen

Johnson & Johnson's Stelara, which brought in more than $9 billion in sales last year, is on its way to losing exclusivity. J&J has been through this before, with another immunology drug called Remicade.

A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.

Allianz SE

BB Seguridade Participacoes SA

Bank of Nova Scotia

Kinder Morgan

Altria

AT&T

U.S. Bancorp

Verizon

High dividend yield companies can help you earn an extra income in the form of dividends, which you can then use to cover your expenses. In this article, I will introduce you to 10 companies that I believe are attractive picks for investors since they combine an attractive Dividend Yield with Dividend Growth.

My Top 10 High Dividend Yield Companies For June 2023

AbbVie

CVS Health

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields - CVS Health (NYSE:CVS), AbbVie (NYSE:ABBV)

Abbott Labs

Automatic Data Processing

Caterpillar

Chubb

Chevron

Vanguard Extended Duration Treasury ETF

W.W. Grainger

KFA Mount Lucas Index Strategy ETF

Novartis

Roche Holding AG

Exxon Mobil

The debt ceiling crisis is coming down to the wire. We're possibly already out of time to prevent default and just don't know it. UBS estimates a short default could create a 20% bear market and a one-month default could lead to a 44% crash.

10 A-Rated Dividend Aristocrats For The Ultimate High-Yield SWAN Portfolio

Medtronic

Medtronic is going through an “aggressive transformation” to boost growth. J&J is spinning off its consumer health business to focus on its higher-growth businesses.

Better Buy: Medtronic vs. Johnson & Johnson

Colgate-Palmolive

Costco

Procter & Gamble

Lowe's

Progressive

With the debt ceiling issue rating as perhaps the single-most critical issue for the market right now, investors should consider targeting safe-haven stocks for debt default. Naturally, the U.S. government defaulting on its obligations would probably spark a ripple effect.

7 Safe-Haven Stocks to Buy for Protection From a U.S. Debt Default Disaster

Exclusive agreement with Janssen PMP, a division of Janssen Pharmaceutica NV, to test MustGrow's mustard-based postharvest food storage preservation technologies for certain applications globally has been extended. Janssen PMP will continue to fund and drive all testing and development work.

MustGrow and Janssen PMP, a Division of Janssen Pharmaceutica NV, Extend Exclusive Global Partnership

Johnson & Johnson's Janssen Biotech Inc has settled its lawsuit against Amgen Inc over Amgen's proposed similar version of J&J's top-selling drug Stelara, according to a filing Monday in Delaware federal court.

Amgen settles J&J patent lawsuit over drug similar to blockbuster Stelara

Advanced Micro Devices

Microsoft

NVIDIA

UnitedHealth Group

Plenty of individual stocks are notching outsized gains this year, with S&P 500 leaders Nvidia Corp. NASDAQ: NVDA and Meta Platforms Inc. NASDAQ: META more than doubling in price. Advanced Micro Devices Inc. NASDAQ: AMD leaped 63.38% higher on AI optimism, while even Royal Caribbean & plc NYSE: RCL is powering forward with a 61% year-to-date gain.

Will Dividends Take Center Stage In The Second Half Of 2023?

Gilead Sciences

AbbVie's current headwinds are only temporary. Gilead Sciences' business remains rock-solid.

3 Relatively Safe Stocks to Buy if a Recession Is on the Way

Applied Materials

Cabot

Discover

Evercore

National Bank Hlds

Schwab US Dividend Equity ETF

Tetra Tech

All these stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 10.8% and a median increase of 8.1%.

7 Upcoming Dividend Increases, Including 1 Dividend King

American Express

Disney

JPMorgan Chase & Co

Walgreens

If you're looking to build a portfolio of high-quality blue chip stocks, Dow stocks should be at or near the top of your list. These stocks, aka the components of the Dow Jones Industrial Average (or DJIA), represent 30 of America's largest, most venerable companies, across multiple sectors.

7 High-Quality Dow Stocks to Buy on the Dip

McDonald's

Realty Income Corp

Growth investors could learn a thing or two from income-oriented investors when it comes to reliable dividend stocks. Not only do these dividend stocks pay a healthy and consistent yield, many of these names trade quite well too.

3 Reliable Dividend Stocks That Fit in Any Investor's Portfolio

There is more to the comparison, and in the sections below, we discuss why we believe BMY stock will offer higher returns than JNJ stock in the next three years.

Which Pharmaceuticals Stock Is A Better Pick: Johnson & Johnson Or Eliquis' Maker?

News for Johnson & Johnson Stock (JNJ)